Please login to the form below

Not currently logged in
Email:
Password:

Sutent

This page shows the latest Sutent news and features for those working in and with pharma, biotech and healthcare.

Merck’s Bavencio joins first-line kidney cancer face-off

Merck’s Bavencio joins first-line kidney cancer face-off

39% reduction in progression-free survival (PFS) for the duo versus Pfizer’s Sutent (sunitinib), which has been the reference standard for first-line RCC treatment for a decade, in ... There was a significant benefit regardless of whether the

Latest news

More from news
Approximately 4 fully matching, plus 89 partially matching documents found.

Latest Intelligence

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    The JAVELIN Renal 101 trial combining Bavencio with Inlyta in previously untreated advanced renal cell carcinoma recently showed itself to be superior in progression- free survival (PFS) compared with Sutent.

  • Accelerating innovation Accelerating innovation

    Phase II results from its CABOSUN trial, in which it was compared with Sutent in previously untreated advanced RCC, were released at this year’s European Society for Medical Oncology (ESMO) ... The new trial of previously untreated patients with

  • Charting a course for expansion Charting a course for expansion

    In addition to meeting the primary endpoint of the study, the trial also showed median progression-free survival of 8.2 months versus Sutent's 5.6 months.

  • Intellectual property threats in the BRIC markets Intellectual property threats in the BRIC markets

    of the compulsory licence process for Herceptin, Sprycel and Ixempra, revocation of a patent for Pfizer's Sutent and a legal ruling allowing a generic version of Tarceva.

  • Building BRICs: pharma's key emerging markets are becoming giants Building BRICs: pharma's key emerging markets are becoming giants

    This follows similar patent defeats in India for Pegasys, Roche's hepatitis drug, Merck's asthma treatment, Singulair, Gilead's Viread (HIV) and Pfizer's Sutent (cancer).

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    Pfizer’ s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines. ... This meant that due to lack of data, there was no benefit found for

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics